Patents by Inventor Alain Taieb

Alain Taieb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective Nox-1 inhibitor peptides and uses thereof
    Patent number: 10517919
    Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: December 31, 2019
    Assignees: Universite de Bordeaux, INSERM
    Inventors: Hamid Reza Rezvani, Frédéric Mazurier, Alain Taieb, L'Emira Ghida Harfouche
  • SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF
    Publication number: 20170340697
    Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 30, 2017
    Inventors: Hamid Reza REZVANI, Frédéric MAZURIER, Alain TAIEB, L'Emira Ghida HARFOUCHE
  • SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF
    Publication number: 20170000842
    Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
    Type: Application
    Filed: January 3, 2014
    Publication date: January 5, 2017
    Inventors: Hamid Reza REZVANI, Frédéric MAZURIER, Alain TAIEB, L'Emira Ghida HARFOUCHE
  • SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF
    Publication number: 20160030503
    Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
    Type: Application
    Filed: January 3, 2014
    Publication date: February 4, 2016
    Inventors: Hamid Reza REZVANI, Frédéric MAZURIER, Alain TAIEB, L'Emira Ghida HARFOUCHE
  • Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
    Patent number: 9173858
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 3, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
    Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
    Patent number: 8338489
    Abstract: The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: December 25, 2012
    Assignee: Université Victor Segalen—Bordeaux 2
    Inventors: Christine Léauté-Labrèze, Éric Dumas De La Roque, Alain Taieb, Jean-Benoît Thambo
  • USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS
    Publication number: 20100273889
    Abstract: The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Application
    Filed: October 16, 2008
    Publication date: October 28, 2010
    Applicant: Universite Victor Segalen- Bordeaux 2
    Inventors: Christine Léauté-Labrèze, Éric Dumas De La Rogue, Alain Taieb, Jean-Benoit Thambo